temozolomide has been researched along with Body Weight in 7 studies
Body Weight: The mass or quantity of heaviness of an individual. It is expressed by units of pounds or kilograms.
| Excerpt | Relevance | Reference |
|---|---|---|
| "8% of actual body weight calculated body surface area dosing was determined for concurrent phase temozolomide." | 8.02 | Actual body weight dosing of temozolomide and overall survival in patients with glioblastoma. ( Chambers, C; Coppens, R; de Robles, P; Dersch-Mills, D; Folkman, F; Ghosh, S; Hsu, PYH; Leckie, C, 2021) |
| " Thus, our results show that polymeric nanocapsules are able to increase the intratumoral bioavailability of indomethacin and reduce the growth of implanted gliomas." | 5.35 | Indomethacin-loaded nanocapsules treatment reduces in vivo glioblastoma growth in a rat glioma model. ( Battastini, AM; Bernardi, A; Braganhol, E; Edelweiss, MI; Figueiró, F; Guterres, SS; Jäger, E; Pohlmann, AR, 2009) |
| "8% of actual body weight calculated body surface area dosing was determined for concurrent phase temozolomide." | 4.02 | Actual body weight dosing of temozolomide and overall survival in patients with glioblastoma. ( Chambers, C; Coppens, R; de Robles, P; Dersch-Mills, D; Folkman, F; Ghosh, S; Hsu, PYH; Leckie, C, 2021) |
| " As a part of the study, two DNA alkylating agents, methylnitrosourea (MNU) and temozolomide (TMZ), were dosed by single oral gavage at 25, 50, and 100mg/kg body weight." | 3.83 | Evaluation of the mutagenicity of alkylating agents, methylnitrosourea and temozolomide, using the rat Pig-a assay with total red blood cells or reticulocytes. ( Ando, M; Inoue, Y; Iwase, Y; Kato, T; Muto, S; Uno, Y; Yamada, K, 2016) |
| "To test the effect of starvation on glioma cells in vitro, we treated primary mouse glia, murine GL26, rat C6 and human U251, LN229 and A172 glioma cells with Temozolomide in ad lib and STS mimicking conditions." | 3.78 | Fasting enhances the response of glioma to chemo- and radiotherapy. ( Brandhorst, S; Chen, TC; Conti, PS; Hwang, S; Lee, C; Longo, VD; Safdie, F; Wang, W; Wei, M, 2012) |
| "Methionine (MET) is a general target in cancer due to the excess requirement of MET by cancer cells." | 1.51 | High Efficacy of Recombinant Methioninase on Patient-Derived Orthotopic Xenograft (PDOX) Mouse Models of Cancer. ( Han, Q; Hoffman, RM; Igarashi, K; Kawaguchi, K; Li, S; Murakami, T; Tan, Y, 2019) |
| " Thus, our results show that polymeric nanocapsules are able to increase the intratumoral bioavailability of indomethacin and reduce the growth of implanted gliomas." | 1.35 | Indomethacin-loaded nanocapsules treatment reduces in vivo glioblastoma growth in a rat glioma model. ( Battastini, AM; Bernardi, A; Braganhol, E; Edelweiss, MI; Figueiró, F; Guterres, SS; Jäger, E; Pohlmann, AR, 2009) |
| " PaTrin-2 effectively inactivated MGMT in MCF-7 cells (IC(50) approximately 6 nM) and in xenografts there was complete inactivation of MGMT within 2 h of dosing (20 mg kg(-1) i." | 1.33 | O6-(4-bromothenyl)guanine reverses temozolomide resistance in human breast tumour MCF-7 cells and xenografts. ( Clemons, M; Howell, A; Kelly, J; Margison, GP; McElhinney, RS; McMurry, TB; Watson, AJ, 2005) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (14.29) | 18.2507 |
| 2000's | 2 (28.57) | 29.6817 |
| 2010's | 3 (42.86) | 24.3611 |
| 2020's | 1 (14.29) | 2.80 |
| Authors | Studies |
|---|---|
| Hsu, PYH | 1 |
| Folkman, F | 1 |
| Ghosh, S | 1 |
| de Robles, P | 1 |
| Leckie, C | 1 |
| Dersch-Mills, D | 1 |
| Coppens, R | 1 |
| Chambers, C | 1 |
| Hoffman, RM | 1 |
| Murakami, T | 1 |
| Kawaguchi, K | 1 |
| Igarashi, K | 1 |
| Tan, Y | 1 |
| Li, S | 1 |
| Han, Q | 1 |
| Muto, S | 1 |
| Yamada, K | 1 |
| Kato, T | 1 |
| Ando, M | 1 |
| Inoue, Y | 1 |
| Iwase, Y | 1 |
| Uno, Y | 1 |
| Bernardi, A | 1 |
| Braganhol, E | 1 |
| Jäger, E | 1 |
| Figueiró, F | 1 |
| Edelweiss, MI | 1 |
| Pohlmann, AR | 1 |
| Guterres, SS | 1 |
| Battastini, AM | 1 |
| Safdie, F | 1 |
| Brandhorst, S | 1 |
| Wei, M | 1 |
| Wang, W | 1 |
| Lee, C | 1 |
| Hwang, S | 1 |
| Conti, PS | 1 |
| Chen, TC | 1 |
| Longo, VD | 1 |
| Clemons, M | 1 |
| Kelly, J | 1 |
| Watson, AJ | 1 |
| Howell, A | 1 |
| McElhinney, RS | 1 |
| McMurry, TB | 1 |
| Margison, GP | 1 |
| Wedge, SR | 1 |
| Newlands, ES | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Evaluation of Topical Application of 5% Imiquimod, 0.05% Imiquimod and 0.05% Nanoencapsulated Imiquimod Gel in the Treatment of Actinic Cheilitis: a Randomized Controlled Trial[NCT04219358] | Phase 1 | 49 participants (Actual) | Interventional | 2019-03-23 | Terminated (stopped due to Study terminated because of COVID19 pandemics.) | ||
| A Feasibility Pilot Trial Evaluating Caloric Restriction for Oncology Research in Early Stage Breast Cancer Patients[NCT01819233] | 38 participants (Actual) | Interventional | 2013-03-08 | Completed | |||
| Can Fasting Decrease the Side Effects of Chemotherapy?[NCT04027478] | 39 participants (Anticipated) | Interventional | 2019-09-01 | Enrolling by invitation | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Analyzed via a paired t-test. Change in body fat measurement as determined by the Durnin-Womersley 4-fold technique (NCT01819233)
Timeframe: Baseline to 4 weeks after completion of study
| Intervention | percentage of change in body fat (Mean) |
|---|---|
| Behavioral Dietary Intervention | -3.1 |
Assessed via mixed-effects regression. Weight changes over time assessed by modeling BMI as a function of time (NCT01819233)
Timeframe: Baseline to 4 weeks after completion of study
| Intervention | percentage of change in BMI (Mean) |
|---|---|
| Behavioral Dietary Intervention | -1.2 |
Assessed via mixed-effects regression. (NCT01819233)
Timeframe: Baseline to 4 weeks after completion of study
| Intervention | beats per minute (Mean) |
|---|---|
| Behavioral Dietary Intervention | 67.3 |
Analyzed via survival methods, specifically the Kaplan-Meier method and the logrank test. (NCT01819233)
Timeframe: Up to 4 weeks after completion of study
| Intervention | Participants (Count of Participants) |
|---|---|
| Behavioral Dietary Intervention | NA |
Analyzed via survival methods, specifically the Kaplan-Meier method and the logrank test. (NCT01819233)
Timeframe: Up to 4 weeks after completion of study
| Intervention | Participants (Count of Participants) |
|---|---|
| Behavioral Dietary Intervention | NA |
Computed along with a 95% exact confidence interval. Exact binomial test (with a one-sided alpha of 0.05) will be used to test whether adherence is greater than 60%. (NCT01819233)
Timeframe: Up to week 12
| Intervention | participants (Number) |
|---|---|
| Behavioral Dietary Intervention | 28 |
Analyzed via survival methods, specifically the Kaplan-Meier method and the logrank test. (NCT01819233)
Timeframe: Up to 4 weeks after completion of study
| Intervention | Participants (Count of Participants) |
|---|---|
| Behavioral Dietary Intervention | NA |
Assessed via mixed-effects regression. The FACT-B is a questionnaire using a 5-point Likert scale (0-Not at all to 4-Very much) (NCT01819233)
Timeframe: Baseline to 4 weeks after completion of study
| Intervention | score on a scale (Mean) |
|---|---|
| Behavioral Dietary Intervention | 0.8 |
Analyzed via survival methods, specifically the Kaplan-Meier method and the logrank test. (NCT01819233)
Timeframe: Up to 4 weeks after completion of study
| Intervention | Participants (Count of Participants) |
|---|---|
| Behavioral Dietary Intervention | NA |
7 other studies available for temozolomide and Body Weight
| Article | Year |
|---|---|
Actual body weight dosing of temozolomide and overall survival in patients with glioblastoma.
Topics: Adult; Antineoplastic Agents, Alkylating; Body Weight; Brain Neoplasms; Combined Modality Therapy; D | 2021 |
High Efficacy of Recombinant Methioninase on Patient-Derived Orthotopic Xenograft (PDOX) Mouse Models of Cancer.
Topics: Animals; Body Weight; Carbon-Sulfur Lyases; Cell Proliferation; Humans; Mice, Nude; Mutation; Neopla | 2019 |
Evaluation of the mutagenicity of alkylating agents, methylnitrosourea and temozolomide, using the rat Pig-a assay with total red blood cells or reticulocytes.
Topics: Alkylating Agents; Animals; Body Weight; Dacarbazine; Erythrocytes; Male; Membrane Proteins; Methyln | 2016 |
Indomethacin-loaded nanocapsules treatment reduces in vivo glioblastoma growth in a rat glioma model.
Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Body Weight; Cell Division; Cell | 2009 |
Fasting enhances the response of glioma to chemo- and radiotherapy.
Topics: Animals; Antineoplastic Agents, Alkylating; Astrocytoma; Blood Glucose; Body Weight; Brain Neoplasms | 2012 |
Fasting enhances the response of glioma to chemo- and radiotherapy.
Topics: Animals; Antineoplastic Agents, Alkylating; Astrocytoma; Blood Glucose; Body Weight; Brain Neoplasms | 2012 |
Fasting enhances the response of glioma to chemo- and radiotherapy.
Topics: Animals; Antineoplastic Agents, Alkylating; Astrocytoma; Blood Glucose; Body Weight; Brain Neoplasms | 2012 |
Fasting enhances the response of glioma to chemo- and radiotherapy.
Topics: Animals; Antineoplastic Agents, Alkylating; Astrocytoma; Blood Glucose; Body Weight; Brain Neoplasms | 2012 |
O6-(4-bromothenyl)guanine reverses temozolomide resistance in human breast tumour MCF-7 cells and xenografts.
Topics: Animals; Body Weight; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Dacarbazine; Drug Resi | 2005 |
O6-benzylguanine enhances the sensitivity of a glioma xenograft with low O6-alkylguanine-DNA alkyltransferase activity to temozolomide and BCNU.
Topics: Animals; Antineoplastic Agents; Astrocytoma; Body Weight; Carmustine; Cell Division; Cell Line; Daca | 1996 |